19 Jun 2020 Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)
18 Jun 2020 Seattle Genetics Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates
18 Jun 2020 Genentech’s Tecentriq in Combination With Chemotherapy (Including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response, Regardless of PD-L1 Status, as Initial Treatment for People With Early Triple-negative Breast Cancer
17 Jun 2020 CORAT Therapeutics Takes Over the Fast Track Development of a Novel COVID-19 Antibody Drug Program
17 Jun 2020 RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
17 Jun 2020 Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology
17 Jun 2020 FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA® (pembrolizumab), Regardless of Tumor Type
17 Jun 2020 FDA Approves First Treatment for Adult Onset Still’s Disease, a Severe and Rare Disease
17 Jun 2020 Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
17 Jun 2020 FDA approves gemtuzumab ozogamicin for CD33-positive AML in pediatric patients
15 Jun 2020 Momenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG)
15 Jun 2020 Mayo Clinic Study of Humanigen’s Lenzilumab Shows Rapid Recovery and Discharge in Severe and Critical COVID-19 Patients
13 Jun 2020 Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual Meeting
13 Jun 2020 AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks
13 Jun 2020 First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara® at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis
13 Jun 2020 ALX Oncology Presents Preliminary Phase 1 Study Results of ALX148 in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
13 Jun 2020 ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
13 Jun 2020 Subcutaneous Formulation of DARZALEX®▼(Daratumumab) Combination Resulted in Deep and Rapid Haematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
12 Jun 2020 Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
11 Jun 2020 World's first iLDC enabling ADC drug receives IND clearance by the US FDA
11 Jun 2020 Regeneron Begins First Clinical Trials of Anti-Viral Antibody Cocktail REGN-COV2 for the Treatment and Prevention of COVID-19
11 Jun 2020 LEO Pharma Announces European Medicines Agency Acceptance of Marketing Authorization Application for tralokinumab for the Treatment of Adults With Moderate-To-Severe Atopic Dermatitis
11 Jun 2020 U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based Chemotherapy
10 Jun 2020 Twist Bioscience Partners with Serimmune to Identify SARS-CoV-2 Therapeutic Antibody Candidates
10 Jun 2020 Opthea Reports Positive Phase 2a Trial Results of OPT-302 in Diabetic Macular Edema

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up